Saturday, 5 September 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 6, 2026

Eli Lilly reports broad benefits for experimental obesity drug retatrutide

View original at seekingalpha.com
Eli Lilly reports broad benefits for experimental obesity drug retatrutide [Worried mature man measuring his waist in a living room] Ljupco/iStock via Getty Images Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]) on Saturday reported positive results from two late-stage clinical trials of its experimental obesity…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • In TRANSCEND-T2D-1, retatrutide reduced A1C levels by up to 2 percentage points over 40 weeks in type 2 diabetes patients starting at an average A1C of 7.9%

    60% confidence
  • Up to 90% of type 2 diabetes patients receiving retatrutide achieved A1C below 7%; nearly half reached A1C below 5.7% (normal range)

    60% confidence
  • Retatrutide reduced knee osteoarthritis pain scores by as much as 73%

    60% confidence
  • Highest-dose T2D patients lost average 36.6 pounds (16.8% body weight) and weight loss had not yet leveled off by study end

    60% confidence
  • More than 65% of highest-dose TRIUMPH-1 participants reduced BMI below 30, no longer meeting the medical definition of obesity

    60% confidence
  • About one-third of highest-dose participants reached a BMI below 25, generally considered a healthy weight range

    60% confidence
  • Retatrutide improved triglycerides, non-HDL cholesterol, blood pressure, and waist circumference across both studies

    60% confidence
  • Retatrutide reduced breathing interruptions in obstructive sleep apnea by up to 36.1 events per hour, representing roughly a 61% improvement

    60% confidence
  • Discontinuation rates due to side effects ranged from approximately 2% to 11% depending on study and dose level

    60% confidence
  • In TRIUMPH-1, adults with obesity receiving the highest dose of retatrutide lost an average of 70.3 pounds (28.3% body weight) after 80 weeks

    60% confidence
  • GLP-1 drug market sales forecast raised to $150 billion

    60% confidence
  • Among more severely obese participants treated for two years, average weight loss reached 85 pounds (38.56 kg)

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com
Eli Lilly reports broad benefits for experimental obesity drug retatrutide — Source | Via News | ViaNews EU